The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Allergy |
Vol/bind | 57 |
Udgave nummer | 4 |
Sider (fra-til) | 297-305 |
Antal sider | 9 |
ISSN | 0105-4538 |
Status | Udgivet - apr. 2002 |
ID: 50845610